Funding Opportunities

Purpose: this Funding Opportunity Announcement (FOA) encourages joint applications for the Global Infectious Disease (GID) Research Training programs from U.S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of a LMIC institution to conduct infectious disease research not including HIV/AIDS. FIC will support research-training programs that focus on major endemic or life-threatening emerging infectious diseases, neglected tropical diseases, infections that frequently occur as co-infections in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs.  Training related to prevention, treatment or public health approaches to any technical area of basic, epidemiology, clinical, behavioral or social science health research may be supported.  Research Training programs should incorporate didactic, mentored research and professional development skills components to prepare individuals for careers that will have significant impact on the priority health research needs of LMICs.

This Funding Opportunity Announcement (FOA) allows support of trainees as the lead investigator of an independent clinical trial; or a separate ancillary clinical trial or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and professional development.

Application Due Date(s): August 14, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

https://grants.nih.gov/grants/guide/pa-files/PAR-20-229.html

Funding Opportunity Purpose: The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

Application Due Date(s): The first standard application due date for this FOA is June 16, 2020. Standard dates apply.

AIDS Application Due Date(s): The first AIDS application due date for this FOA is September 7, 2020. Standard AIDS dates apply.

All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Companion Funding Opportunity

PA-20-194, NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Required)

PA-20-195, NIH Exploratory/Developmental Research Grant Program (Parent R21, Clinical Trial Not Allowed)

Application Due Date(s): July 15, 2020; July 15, 2021; July 15 2022, by 5:00 PM local time of applicant organization.
AIDS Application Due Date(s): August 19, 2020; August 19, 2021; August 19, 2022, by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) encourages applications from organizations/institutions in eligible foreign countries that propose research related to infectious diseases that are of interest/importance to that country.

https://grants.nih.gov/grants/guide/pa-files/PAR-20-108.html

Inhibition of Host Heme Oxygenase-1 as an Adjunctive Treatment to Improve the Outcome of Conventional Antibiotic Chemotherapy of Mycobacterium tuberculosis (Mtb) Infection

This invention describes the adjunctive use of heme oxygenase-1 (HO-1) inhibitors to improve the outcome of conventional antibiotic treatment for tuberculosis. The existent standard of care requires prolonged administration of drug. Due to the long duration of treatment, methods that can more rapidly control tuberculosis in patients are clearly needed.

NIAID researchers have discovered that inhibition of host HO-1 reduces Mycobacterium tuberculosis (Mtb) growth in vivo and, more importantly, when used as an adjunct to conventional chemotherapy, results in a marked improvement in pulmonary bacterial control. In particular, it was found using a mouse model that HO-1 inhibitors enhance bacterial clearance when used in conjunction with conventional antibiotic therapy. Further, no obvious toxic side effects were found. Since this host-directed strategy does not directly target the pathogen itself, it may have an added advantage as a treatment for infections with antibiotic-resistant Mtb strains.

Licensing Contact:
James Robinson,
Email: james.robinson4@nih.gov
Phone: 301-761-7542

More information: https://www.ott.nih.gov/technology/e-174-2016

Due Dates: January 8, 2020; January 8, 2021; January 10, 2022

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical, preclinical and non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis.

R01: https://grants.nih.gov/grants/guide/pa-files/PAR-19-357.html

R21: https://grants.nih.gov/grants/guide/pa-files/par-19-364.html

Application Due Date(s): Standard dates apply , by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

https://grants.nih.gov/grants/guide/pa-files/PA-18-725.html

https://grants.nih.gov/grants/guide/pa-files/PA-18-724.html

Application Due Date(s): Standard dates apply , by 5:00 PM local time of applicant organization.

The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.

https://grants.nih.gov/grants/guide/pa-files/PA-18-350.html

Application Due Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. 

R01: https://grants.nih.gov/grants/guide/pa-files/PAR-19-274.html

R21: https://grants.nih.gov/grants/guide/pa-files/par-19-275.html

R03: https://grants.nih.gov/grants/guide/pa-files/par-19-276.html

Application Due Date(s): November 7, 2019 and November 4, 2020 by 5:00 PM local time of applicant organization.

The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-len…, including “low-income,” “lower-middle-income,” and “upper-middle-income” countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors.

https://grants.nih.gov/grants/guide/pa-files/PAR-19-098.html

Application Due Date(s): July 28, 2021; July 28, 2022; July 28, 2023, by 5:00 PM local time of applicant organization.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications from research institutions in low- to middle-income countries (LMIC) to provide senior administrators from these institutions with advanced training in the management of NIH grants. The ultimate goal is to improve oversight of NIAID grant awards and compliance with NIH funding policies and Federal research funding requirements for NIAID-supported foreign institutions in low to middle-income countries.

https://grants.nih.gov/grants/guide/pa-files/PAR-21-037.html